aldosterone has been researched along with Coronavirus Infections in 11 studies
Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 11 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bornstein, SR | 1 |
Dalan, R | 1 |
Hopkins, D | 1 |
Mingrone, G | 1 |
Boehm, BO | 1 |
Henry, BM | 1 |
Vikse, J | 1 |
Benoit, S | 1 |
Favaloro, EJ | 1 |
Lippi, G | 1 |
Alexandre, J | 1 |
Cracowski, JL | 1 |
Richard, V | 1 |
Bouhanick, B | 1 |
Mareev, YV | 1 |
Mareev, VY | 1 |
Pechère-Bertschi, A | 1 |
Ponte, B | 1 |
Wuerzner, G | 1 |
Curfman, G | 1 |
Dudoignon, E | 1 |
Moreno, N | 1 |
Deniau, B | 1 |
Coutrot, M | 1 |
Longer, R | 1 |
Amiot, Q | 1 |
Mebazaa, A | 1 |
Pirracchio, R | 1 |
Depret, F | 1 |
Legrand, M | 1 |
Culebras, E | 1 |
Hernández, F | 1 |
Otto, CM | 1 |
Young, MJ | 1 |
Clyne, CD | 1 |
Chapman, KE | 1 |
Mabillard, H | 2 |
Sayer, JA | 2 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization[NCT04661930] | Phase 3 | 55 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
Time of Recovery and Prognostic Factors of COVID-19 Pneumonia[NCT04324684] | 198 participants (Actual) | Observational | 2020-03-31 | Completed | |||
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19[NCT05736900] | 200 participants (Actual) | Interventional | 2020-09-10 | Completed | |||
Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.[NCT04480034] | 1,600 participants (Anticipated) | Observational | 2020-07-15 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
Intervention | Participants (Count of Participants) |
---|---|
Fenofibrate + Usual Care | 19 |
Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.03 |
Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Median) |
---|---|
Fenofibrate + Usual Care | 30 |
Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Mean) |
---|---|
Fenofibrate + Usual Care | 28.8 |
Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
Intervention | Ranked Severity Score (Median) |
---|---|
Fenofibrate + Usual Care | 5.32 |
Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.05 |
Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 1 |
Placebo + Usual Care | 1 |
4 reviews available for aldosterone and Coronavirus Infections
Article | Year |
---|---|
Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immunity, Innate; Inflammati | 2020 |
Renin-angiotensin-aldosterone system and COVID-19 infection.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-C | 2020 |
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Bet | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
7 other studies available for aldosterone and Coronavirus Infections
Article | Year |
---|---|
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2020 |
[Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?]
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensins | 2020 |
Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2020 |
Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19.
Topics: Acute Kidney Injury; Aged; Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Creatinin | 2020 |
ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
Topics: Aldosterone; Angiotensins; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Heart Failure; | 2020 |
Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2020 |